Hydroxocobalamin G.L. Pharma (Hydroxocobalamin Acetate)

Hydroxocobalamin serves as a cofactor for methionine synthase and methylmalonyl‑CoA mutase, enzymes essential for converting homocysteine to methionine and for fatty‑acid metabolism. This activity enables proper DNA synthesis, myelin formation, and red blood cell production, correcting the metabolic disturbances caused by B12 deficiency.

The dosage of Hydroxocobalamin G.L. Pharma is determined by the prescribing clinician based on the patient’s specific condition, severity of deficiency, and route of administration. Healthcare providers set the appropriate dose and schedule according to clinical guidelines and individual patient needs.

Hydroxocobalamin may be used during pregnancy or lactation only when clearly needed and after a careful risk‑benefit assessment by the prescriber. Vitamin B12 is essential for fetal development, but the decision to treat should be individualized and discussed with a healthcare professional.

To order Hydroxocobalamin G.L. Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Hydroxocobalamin is a naturally occurring form of vitamin B12 with a longer plasma half‑life compared with cyanocobalamin, allowing more sustained B12 levels. It is often preferred for patients with severe deficiency or malabsorption because it can be administered intramuscularly or subcutaneously, bypassing gastrointestinal absorption.

Hydroxocobalamin G.L. Pharma should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the product. If the solution appears discolored or contains particles, it should not be used.

Hydroxocobalamin G.L. Pharma is administered by a healthcare professional via intramuscular or subcutaneous injection. The injection site is typically the deltoid or gluteal muscle, and the volume and concentration are determined by the prescriber based on the therapeutic indication.

The most serious risks include rare anaphylactic reactions, severe hypotension, pulmonary edema, and thromboembolic events. Patients should be monitored during and after injection for signs of allergic response, cardiovascular changes, or respiratory distress, and immediate medical attention should be sought if serious symptoms occur.

Hydroxocobalamin G.L. Pharma should be avoided in individuals with a known hypersensitivity to cobalamin preparations or any of the excipients in the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled cardiovascular disease, or those who have experienced previous severe reactions to vitamin B12 injections.